MGC Pharmaceuticals Ltd.

MGC Pharma appoints new UK based Chief Financial Officer

26 April 2022

ASX, LSE: MXC

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce the appointment of Ms Angela-Marie Graham as its new London based Chief Financial Officer.

Ms Graham has over 25 years of accountancy experience, specialising in growth businesses in emerging industries, including those within the biopharmaceutical sector. Prior to joining MGC Pharma, Ms Graham worked at a UK based consultancy offering commercial, fundraising, planning and strategic guidance for high growth start-ups and SMEs. Prior to this, Angela-Marie spent seven years as Finance Director of a UK fund raising organisation,  and has experience working for companies with international operations.

As  part of MGC Pharma's business strategy to establish the Company's corporate office in the UK to support its European operational centres, following its listing on the London Stock Exchange in February 2021, Ms Graham's role as Group CFO will be based in London.  The Company has also recently appointed a new group Financial Controller in London as part of the Company's new finance team operating base in the UK.

Ms Graham holds a degree in Business Studies from the London Metropolitan University, and is a fellow of the Association of Chartered Certified Accountants (ACCA).

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "I'm delighted that we have been able to hire someone of Angela's expertise to the role of Group CFO for our global business and we are all very much looking forward to working with her.

"MGC Pharma has made great progress over the past 18 months, growing sales strongly in established and new markets with each quarter, as well as advancing our clinical pipeline. I am confident that Angela will help us to continue along this pathway towards continued commercial and operational success, particularly with her experience working with biopharma businesses."

--Ends-

Authorised for release by the Managing Director, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - Epilepsy and Dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma